Literature DB >> 9743366

Prostaglandin E2 protects against liver injury after Escherichia coli infection but hampers the resolution of the infection in mice.

M Takano1, H Nishimura, Y Kimura, J Washizu, Y Mokuno, Y Nimura, Y Yoshikai.   

Abstract

cAMP-increasing agents such as prostaglandin E2 (PGE2) are known to protect against LPS-induced liver injury by downregulating the production of inflammatory cytokines such as TNF-alpha. However, the effects of such reagents on host defense against bacterial infection remain unknown. We show here that in vivo administration of PGE2 significantly protected mice against liver injury after Escherichia coli infection but hampered the resolution of the infection. PGE2 significantly suppressed circulating TNF-alpha and IL-12 levels but increased the IL-10 production after E. coli challenge. PGE2 inhibited the emergence of gammadelta T cells in the peritoneal cavity, which are important for host defense against E. coli, and deteriorated bacterial exclusion in the peritoneal cavity after E. coli challenge. These results suggested that PGE2 affects host defense mechanisms against E. coli infection through modulation of cytokine production and gammadelta T cell accumulation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9743366

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

Review 1.  IL-12 as a therapeutic target for pharmacological modulation in immune-mediated and inflammatory diseases: regulation of T helper 1/T helper 2 responses.

Authors:  G Haskó; C Szabó
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

2.  Microsomal prostaglandin E synthase-1 protects against Fas-induced liver injury.

Authors:  Lu Yao; Weina Chen; Chang Han; Tong Wu
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-04-21       Impact factor: 4.052

3.  Salmonella enterica serovar Typhimurium infection induces cyclooxygenase 2 expression in macrophages: involvement of Salmonella pathogenicity island 2.

Authors:  Kei-ichi Uchiya; Toshiaki Nikai
Journal:  Infect Immun       Date:  2004-12       Impact factor: 3.441

4.  The ceramide-1-phosphate analogue PCERA-1 modulates tumour necrosis factor-alpha and interleukin-10 production in macrophages via the cAMP-PKA-CREB pathway in a GTP-dependent manner.

Authors:  Dorit Avni; Amir Philosoph; Michael M Meijler; Tsaffrir Zor
Journal:  Immunology       Date:  2009-11-16       Impact factor: 7.397

5.  Increased interleukin-10 production and Th2 skewing in the absence of 5-lipoxygenase.

Authors:  Daniel DiMeo; Jun Tian; Juan Zhang; Seiko Narushima; Daniel J Berg
Journal:  Immunology       Date:  2007-09-25       Impact factor: 7.397

6.  Antibiotic pretreatment alleviates liver transplant damage in mice and humans.

Authors:  Kojiro Nakamura; Shoichi Kageyama; Takahiro Ito; Hirofumi Hirao; Kentaro Kadono; Antony Aziz; Kenneth J Dery; Matthew J Everly; Kojiro Taura; Shinji Uemoto; Douglas G Farmer; Fady M Kaldas; Ronald W Busuttil; Jerzy W Kupiec-Weglinski
Journal:  J Clin Invest       Date:  2019-07-22       Impact factor: 14.808

Review 7.  How apoptotic β-cells direct immune response to tolerance or to autoimmune diabetes: a review.

Authors:  Marta Vives-Pi; Silvia Rodríguez-Fernández; Irma Pujol-Autonell
Journal:  Apoptosis       Date:  2015-03       Impact factor: 4.677

Review 8.  E-type prostanoid receptor 4 (EP4) in disease and therapy.

Authors:  Viktoria Konya; Gunther Marsche; Rufina Schuligoi; Akos Heinemann
Journal:  Pharmacol Ther       Date:  2013-03-21       Impact factor: 12.310

9.  Transcriptomic analysis of peritoneal cells in a mouse model of sepsis: confirmatory and novel results in early and late sepsis.

Authors:  Minny Bhatty; Ruping Fan; William M Muir; Stephen B Pruett; Bindu Nanduri
Journal:  BMC Genomics       Date:  2012-09-25       Impact factor: 3.969

10.  Xiao-Yin-Fang Therapy Alleviates Psoriasis-like Skin Inflammation Through Suppressing γδT17 Cell Polarization.

Authors:  Xilin Zhang; Xiaorui Li; Youdong Chen; Bingjie Li; Chunyuan Guo; Peng Xu; Zengyang Yu; Yangfeng Ding; Yuling Shi; Jun Gu
Journal:  Front Pharmacol       Date:  2021-04-16       Impact factor: 5.810

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.